Search Results 101-110 of 16814 for 4-week HIIT protocol

  1. Phase I/II Cancer Caregiver Interventions to Improve Quality of Life and Prevent Burnout - Mayo Clinic

    Sponsor Protocol Number: MC1295. About this study ... week over a 4-week period. Participation ... Guidelines differ from study to study, and identify who can or ...

  2. Neurosurgery - Clinical trials

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

  3. Olmsted County, Minnesota Air Quality (OMAQ) Study - Mayo Clinic

    Sponsor Protocol Number: 18-003033. About this ... 4-week period. Participation eligibility ... Guidelines differ from study to study, and identify who can or ...

  4. A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis - Mayo Clinic

    ... 4 weeks prior to Baseline (Visit 2). Or: Within 6 months prior to Screening (Visit 1), recurrence of symptoms of EGPA (not necessarily meeting the protocol ...

  5. Neurosurgery - Clinical trials

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

  6. Hematology - Clinical trials

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

  7. Vaginal Microbiome Changes in Pessary Users - Mayo Clinic

    Currently using antibiotics or used within 4 weeks of initial vaginal swab; Having BV or vaginitis at the time of recruitment. Note: Other protocol defined ...

  8. Neurology - Clinical trials - Mayo Clinic

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

  9. Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in patients ...

  10. Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) - Mayo Clinic

    The study will comprise of a screening period of up to approximately 4 weeks followed by a 32-Week study treatment period (subjects will be randomized 1:1 ...